Denk Pharma GmbH & Co. KG

denkpharma.de

DENK PHARMA is a global company with core competence in the area of health care. DENK PHARMA was founded in Munich, Germany in 1948. We have a strong focus on export markets and presently supply our DENK PHARMA premium medicine and food supplements around the world. For more than 70 years, we have delivered quality that is “Made in Germany” – we manufacture, quality control and register all of our products in Germany. This enables us to ensure that all patients worldwide receive the same high-quality as they do in Germany.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

INSITRO APPOINTS PHILIP TAGARI, INDUSTRY-LEADING SCIENTIST AND DRUG HUNTER, AS CHIEF SCIENTIFIC OFFICER

insitro | December 02, 2022

news image

insitro, a machine learning-powered drug discovery and development company announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery. “I am deeply excited to partner with Philip on insitro’s journey to build a transformative biology platform for...

Read More

Pharma Tech

PALATIN ANNOUNCES INTENT TO EFFECT REVERSE STOCK SPLIT

Palatin Technologies, Inc. | August 20, 2022

news image

Palatin Technologies, Inc. a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock. The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on August 30, 2022 and the Company's common stock is expected to begin trading on a split-adjusted basis when t...

Read More

Business Insights

HIKMA STRENGTHENS US INJECTABLES BUSINESS THROUGH ACQUISITION OF CUSTOPHARM

Hikma Pharmaceuticals USA Inc. | September 27, 2021

news image

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'). Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certa...

Read More

Business Insights

UCB SHOWCASES STRENGTH OF THE EXPANDING DERMATOLOGY PORTFOLIO AT THE 31ST EADV CONGRESS

UCB, Inc. | September 02, 2022

news image

UCB, a global biopharmaceutical company, today announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, September 7-10. The abstracts, accepted for poster presentation, underscore UCB's commitment to delivering innovative solutions that aim to address the unmet needs of people living with dermatological diseases. "We are proud to present new data from our expan...

Read More
news image

Business Insights, PHARMACY MARKET

INSITRO APPOINTS PHILIP TAGARI, INDUSTRY-LEADING SCIENTIST AND DRUG HUNTER, AS CHIEF SCIENTIFIC OFFICER

insitro | December 02, 2022

insitro, a machine learning-powered drug discovery and development company announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a 24-year career at Amgen, where he has led the organization's research platforms for over a decade as vice president, research - therapeutic discovery. “I am deeply excited to partner with Philip on insitro’s journey to build a transformative biology platform for...

Read More
news image

Pharma Tech

PALATIN ANNOUNCES INTENT TO EFFECT REVERSE STOCK SPLIT

Palatin Technologies, Inc. | August 20, 2022

Palatin Technologies, Inc. a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock. The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on August 30, 2022 and the Company's common stock is expected to begin trading on a split-adjusted basis when t...

Read More
news image

Business Insights

HIKMA STRENGTHENS US INJECTABLES BUSINESS THROUGH ACQUISITION OF CUSTOPHARM

Hikma Pharmaceuticals USA Inc. | September 27, 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'). Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certa...

Read More
news image

Business Insights

UCB SHOWCASES STRENGTH OF THE EXPANDING DERMATOLOGY PORTFOLIO AT THE 31ST EADV CONGRESS

UCB, Inc. | September 02, 2022

UCB, a global biopharmaceutical company, today announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, September 7-10. The abstracts, accepted for poster presentation, underscore UCB's commitment to delivering innovative solutions that aim to address the unmet needs of people living with dermatological diseases. "We are proud to present new data from our expan...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us